Role of 90K/Mac-2 BP as an Indicator of Early Response to Infliximab Therapy in IBD Patients

Launched by ASSIUT UNIVERSITY · Jul 18, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new blood test, called 90K, to see if it can help doctors understand how well a treatment called infliximab is working for patients with inflammatory bowel disease (IBD). The researchers want to find out if measuring the levels of 90K in the blood before and after starting infliximab can give important information about the patient’s response to the therapy. This could help doctors make better decisions about managing IBD in patients who are currently experiencing active symptoms.

To participate in this study, individuals must be adults aged 18 to 60 years old who have been diagnosed with IBD through a biopsy. They should not have received any previous treatments with infliximab or other similar therapies. Participants will need to meet certain health criteria, meaning they shouldn’t have significant other health issues or conditions that might complicate their treatment. Since the trial is not yet recruiting, interested patients will need to wait for further announcements. This study could provide valuable insights that might improve treatment strategies for IBD in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult male and female patients aged 18-60 years old.
• • 2. IBD patients, diagnosis was confirmed by biopsy and histopathology, scheduled for treatment with anti-TNF therapy, Infliximab, and no previous treatment with anti-TNF therapy.
• Exclusion Criteria:
• • 1. Comorbidities (assessed with the Charlson Comorbidity Index). 2. Ongoing immunosuppressive or immunomodulatory therapy. 3. A malignant neoplasm in the last 10 years. 4. Pregnancy or breast feeding. 5. The need for artificial nutrition.